NCT03103607 (DISGO) is a clinical trial of Ophthalmological evaluation in Thyroid Eye Disease, sponsored by University of Pisa.

Who is sponsoring NCT03103607?

NCT03103607 is sponsored by University of Pisa.

What drugs are being tested in NCT03103607?

Interventions in NCT03103607: Ophthalmological evaluation, Questionnaire.

What condition does NCT03103607 study?

NCT03103607 studies Thyroid Eye Disease.

Is NCT03103607 still recruiting?

NCT03103607 is currently completed. Last updated 6 April 2017.

Last reviewed 2017-04-06 · How we verify

NCT03103607: DISGO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Disappearance of Graves' Orbitopathy

Completed Last updated 6 April 2017

What this trial tests

trial testing Ophthalmological evaluation in Thyroid Eye Disease in 99 participants. Completed in 28 February 2016.

Timeline

1 January 2010

Primary endpoint
31 December 2014

28 February 2016

Quick facts

Lead sponsor	University of Pisa
Status	Completed
Study type	OBSERVATIONAL
Enrollment	99
Start date	1 January 2010
Primary completion	31 December 2014
Estimated completion	28 February 2016

Drugs / interventions tested

Ophthalmological evaluation
Questionnaire

Conditions studied

Thyroid Eye Disease — all drugs for Thyroid Eye Disease →

Sponsor

University of Pisa

Who can join

Adults 18 to 100, any sex, with Thyroid Eye Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is a general belief among physicians involved with Graves' orbitopathy (GO) that this syndrome is somehow "chronic", namely that the patient's eyes do not return the way they were before GO appeared. The general impression that comes from the available studies is that the eyes of GO patients do not return to normal even after a very long time since the disease appearance under the physician's point of view, although a discrete proportion of patients feel so. However, no studies are available in which the issue was examined with both objective criteria and self-assessment. The present study design was to investigated the disappearance of GO, regardless to treatment, in all consecutive patients with a history of GO of at least 10 years who came for a follow-up visit to our GO clinic over a period of 5 years.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.
Sabini E, Leo M, Mazzi B, Rocchi R, et al · · 2017 · cited 16× · PMID 29071239 · DOI 10.1159/000477803

Verify or expand the search:

Other recruiting trials for Thyroid Eye Disease

Currently open trials in the same condition.

NCT07423013 — Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. · NA · recruiting
NCT07113262 — A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease · Phase 3 · recruiting
NCT06557850 — A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease · Phase 1 · active not recruiting
NCT06625411 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
NCT06625398 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) · Phase 3 · active not recruiting

Other University of Pisa trials

Trials by the same sponsor.

NCT07520890 — Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs) · recruiting
NCT07444229 — Team-Based Learning Integrated Into Clinical Simulation in Nursing Students · NA · not yet recruiting
NCT07041983 — 24-h Energy Expenditure and Anti-obesity Medication · enrolling by invitation
NCT07510685 — Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial) · NA · completed
NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03103607 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pisa
Last refreshed: 6 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03103607.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing